FY2026 EPS Estimates for Zymeworks Reduced by HC Wainwright

Zymeworks Inc. (NASDAQ:ZYME) – Research analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Zymeworks in a research note issued on Tuesday, November 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings of $1.19 per share for the year, down from their previous forecast of $1.51. HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.32 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at $0.05 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at ($0.78) EPS and FY2027 earnings at ($0.39) EPS.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.01. The business had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The company’s revenue was up 828.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.26) earnings per share.

A number of other brokerages have also recently weighed in on ZYME. Jefferies Financial Group reiterated a “buy” rating and set a $52.00 price target on shares of Zymeworks in a research note on Friday, October 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research note on Thursday, October 15th. Truist Financial increased their target price on shares of Zymeworks from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday. Wolfe Research began coverage on Zymeworks in a report on Thursday, September 17th. They set an “outperform” rating on the stock. Finally, Citizens Jmp restated a “market outperform” rating and issued a $32.00 price target on shares of Zymeworks in a research report on Wednesday, August 26th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.67.

Zymeworks Trading Down 7.6%

Shares of ZYME opened at $29.07 on Thursday. The company’s 50 day simple moving average is $27.48 and its 200-day simple moving average is $25.45. The firm has a market cap of $2.01 billion, a PE ratio of 55.90 and a beta of 1.32. Zymeworks has a 12-month low of $18.20 and a 12-month high of $31.97.

Hedge Funds Weigh In On Zymeworks

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZYME. Fisher Asset Management LLC grew its holdings in Zymeworks by 759.9% during the third quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock worth $16,122,000 after acquiring an additional 537,837 shares during the period. Russell Investments Group Ltd. lifted its holdings in Zymeworks by 104.7% in the third quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock valued at $2,596,000 after acquiring an additional 50,127 shares during the period. Calamos Advisors LLC acquired a new stake in Zymeworks in the third quarter valued at $1,232,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zymeworks during the 3rd quarter worth $96,000. Finally, ProShare Advisors LLC boosted its position in shares of Zymeworks by 91.5% during the 3rd quarter. ProShare Advisors LLC now owns 16,390 shares of the company’s stock worth $434,000 after purchasing an additional 7,833 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Transactions at Zymeworks

In related news, EVP Adam Schayowitz sold 13,832 shares of the firm’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the sale, the executive vice president owned 23,205 shares in the company, valued at $599,849.25. This trade represents a 37.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is owned by corporate insiders.

Latest Zymeworks News

Here’s some of the latest news about ZYME:

• Positive Sentiment: Several analysts raised their price targets while maintaining Buy ratings. TD Cowen lifted its target to $39, Truist Financial raised its target to $36, and Citigroup increased its target to $44. HC Wainwright also raised its target to $56 and retained its Buy rating. TD Cowen price-target article Truist Financial article
• Positive Sentiment: Zymeworks reportedly reached a 52-week high after posting better-than-expected quarterly earnings, providing a positive signal about recent performance. Earnings and 52-week high article
• Negative Sentiment: HC Wainwright sharply reduced its earnings estimates for multiple quarters in 2026 and 2027. Its FY2027 forecast moved from earnings of $1.32 per share to a loss of $0.39, while its FY2026 estimate fell from $1.51 to $1.19. These cuts suggest a weaker expected earnings outlook and may be a near-term headwind, despite the firm keeping its Buy rating and $56 target.

Zymeworks Company Profile

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.